NervGen Completes Enrollment in Chronic Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
Topline data from the chronic cohort is expected in Q2 2025 Institutional Review Board (IRB) protocol amendment changes approved, and screening has been initiated for subacute cohort This news release constitutes a “designated news release” for the purposes of NervGen’s prospectus supplement dated December 19, 2024 to its short form base shelf prospectus dated […]
NervGen Announces “At-The-Market” Equity Program
Vancouver, Canada, December 20, 2024 – NervGen Pharma Corp. (“NervGen” or the “Company”) (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, is pleased to announce that it has established an at-the-market equity program (the “ATM Program”) that allows the Company to issue and sell common shares in the capital of […]
NervGen Pharma Reports Q3 2024 Financial Results and Operational Updates
Target enrollment in the chronic cohort of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury (SCI) is approaching completion NVG-300 preclinical test-of-concept studies in ischemic stroke, amyotrophic lateral sclerosis (ALS) and SCI underway Vancouver, Canada, November 14, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech […]
NervGen Pharma to Present at the Stifel 2024 Healthcare Conference
Vancouver, Canada, November 7, 2024 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, announced today that Mr. Mike Kelly, President & CEO, will be participating in a fireside chat at the Stifel 2024 Healthcare Conference on Monday, November 18, 2024, at 10:20 a.m. EST. Members of […]
NervGen Pharma Provides Update on Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
Target enrollment in the chronic cohort close to completion Vancouver, Canada, September 30, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced that target enrollment of the chronic cohort in its Phase 1b/2a proof-of-concept, double-blind, randomized […]
NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th Annual Science & Advocacy Symposium Focused on Spinal Cord Injury
Vancouver, Canada, September 20, 2024 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., NervGen’s Chief Medical Officer, will give an oral presentation at the Unite 2 Fight Paralysis (U2FP) 19th Annual Science […]
NervGen Pharma to Present at the 63rd International Spinal Cord Society Annual Scientific Meeting
Vancouver, Canada, September 16, 2024 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., NervGen’s Chief Medical Officer, will present at the 63rd International Spinal Cord Society (ISCoS) Annual Scientific Meeting, taking place […]
NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Vancouver, Canada, August 27, 2024 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference, on Tuesday, September 10, 2024, at […]
NervGen Pharma Reports Q2 2024 Financial Results and Operational Updates
Targeting to complete enrollment in the Phase 1b/2a chronic cohort in Q3 2024 Protocol being amended to enhance enrollment and lessen burden on participants in the subacute cohort NVG-300 advanced into preclinical proof-of-concept studies in ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI) Vancouver, Canada, August 22, 2024 – NervGen Pharma […]
NervGen Pharma to Present at the Canaccord Genuity 44th Annual Growth Conference
Vancouver, Canada, August 6, 2024 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting at the Canaccord Genuity 44th Annual Growth Conference, on August 13, 2024, at 10:00 a.m. […]
